Guggulsterone and bexarotene induce secretion of exosome-associated breast cancer resistance protein and reduce doxorubicin resistance in MDA-MB-231 cells

Ji Na Kong, Qian He, Guanghu Wang, Somsankar Dasgupta, Michael B. Dinkins, Gu Zhu, Austin Kim, Stefka Spassieva, Erhard Bieberich

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Many breast cancer cells acquire multidrug resistance (MDR) mediated by ABC transporters such as breast cancer resistance protein (BCRP/ABCG2). Here we show that incubation of human breast cancer MDA-MB-231 cells with farnesoid X receptor antagonist guggulsterone (gug) and retinoid X receptor agonist bexarotene (bex) elevated ceramide, a sphingolipid known to induce exosome secretion. The gug+bex combination reduced cellular levels of BCRP to 20% of control cells by inducing its association and secretion with exosomes. Exogenous C6 ceramide also induced secretion of BCRP-associated exosomes, while siRNA-mediated knockdown or GW4869-mediated inhibition of neutral sphingomyelinase 2 (nSMase2), an enzyme generating ceramide, restored cellular BCRP. Immunocytochemistry showed that ceramide elevation and concurrent loss of cellular BCRP was prominent in Aldefluor-labeled breast cancer stem-like cells. These cells no longer excluded the BCRP substrate Hoechst 33342 and showed caspase activation and apoptosis induction. Consistent with reduced BCRP, ABC transporter assays showed that gug+bex increased doxorubicin retention and that the combination of gug+bex with doxorubicin enhanced cell death by more than fivefold. Taken together, our results suggest a novel mechanism by which ceramide induces BCRP secretion and reduces MDR, which may be useful as adjuvant drug treatment for sensitizing breast cancer cells and cancer stem cells to chemotherapy.

Original languageEnglish (US)
Pages (from-to)1610-1620
Number of pages11
JournalInternational Journal of Cancer
Volume137
Issue number7
DOIs
StatePublished - Jan 1 2015

Fingerprint

Exosomes
Doxorubicin
Ceramides
Breast Neoplasms
ATP-Binding Cassette Transporters
Neoplastic Stem Cells
Multiple Drug Resistance
Proteins
Retinoid X Receptors
Sphingomyelin Phosphodiesterase
Sphingolipids
Caspases
Small Interfering RNA
Cell Death
Immunohistochemistry
bexarotene
pregna-4,17-diene-3,16-dione
Apoptosis
Drug Therapy
Enzymes

Keywords

  • bile acid
  • breast cancer resistance protein
  • cancer stem cells
  • doxorubicin
  • exosomes
  • multidrug resistance
  • nuclear receptors
  • sphingolipids

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Guggulsterone and bexarotene induce secretion of exosome-associated breast cancer resistance protein and reduce doxorubicin resistance in MDA-MB-231 cells. / Kong, Ji Na; He, Qian; Wang, Guanghu; Dasgupta, Somsankar; Dinkins, Michael B.; Zhu, Gu; Kim, Austin; Spassieva, Stefka; Bieberich, Erhard.

In: International Journal of Cancer, Vol. 137, No. 7, 01.01.2015, p. 1610-1620.

Research output: Contribution to journalArticle

Kong, Ji Na ; He, Qian ; Wang, Guanghu ; Dasgupta, Somsankar ; Dinkins, Michael B. ; Zhu, Gu ; Kim, Austin ; Spassieva, Stefka ; Bieberich, Erhard. / Guggulsterone and bexarotene induce secretion of exosome-associated breast cancer resistance protein and reduce doxorubicin resistance in MDA-MB-231 cells. In: International Journal of Cancer. 2015 ; Vol. 137, No. 7. pp. 1610-1620.
@article{24b2d660b1504189bc7325a596c39c78,
title = "Guggulsterone and bexarotene induce secretion of exosome-associated breast cancer resistance protein and reduce doxorubicin resistance in MDA-MB-231 cells",
abstract = "Many breast cancer cells acquire multidrug resistance (MDR) mediated by ABC transporters such as breast cancer resistance protein (BCRP/ABCG2). Here we show that incubation of human breast cancer MDA-MB-231 cells with farnesoid X receptor antagonist guggulsterone (gug) and retinoid X receptor agonist bexarotene (bex) elevated ceramide, a sphingolipid known to induce exosome secretion. The gug+bex combination reduced cellular levels of BCRP to 20{\%} of control cells by inducing its association and secretion with exosomes. Exogenous C6 ceramide also induced secretion of BCRP-associated exosomes, while siRNA-mediated knockdown or GW4869-mediated inhibition of neutral sphingomyelinase 2 (nSMase2), an enzyme generating ceramide, restored cellular BCRP. Immunocytochemistry showed that ceramide elevation and concurrent loss of cellular BCRP was prominent in Aldefluor-labeled breast cancer stem-like cells. These cells no longer excluded the BCRP substrate Hoechst 33342 and showed caspase activation and apoptosis induction. Consistent with reduced BCRP, ABC transporter assays showed that gug+bex increased doxorubicin retention and that the combination of gug+bex with doxorubicin enhanced cell death by more than fivefold. Taken together, our results suggest a novel mechanism by which ceramide induces BCRP secretion and reduces MDR, which may be useful as adjuvant drug treatment for sensitizing breast cancer cells and cancer stem cells to chemotherapy.",
keywords = "bile acid, breast cancer resistance protein, cancer stem cells, doxorubicin, exosomes, multidrug resistance, nuclear receptors, sphingolipids",
author = "Kong, {Ji Na} and Qian He and Guanghu Wang and Somsankar Dasgupta and Dinkins, {Michael B.} and Gu Zhu and Austin Kim and Stefka Spassieva and Erhard Bieberich",
year = "2015",
month = "1",
day = "1",
doi = "10.1002/ijc.29542",
language = "English (US)",
volume = "137",
pages = "1610--1620",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Guggulsterone and bexarotene induce secretion of exosome-associated breast cancer resistance protein and reduce doxorubicin resistance in MDA-MB-231 cells

AU - Kong, Ji Na

AU - He, Qian

AU - Wang, Guanghu

AU - Dasgupta, Somsankar

AU - Dinkins, Michael B.

AU - Zhu, Gu

AU - Kim, Austin

AU - Spassieva, Stefka

AU - Bieberich, Erhard

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Many breast cancer cells acquire multidrug resistance (MDR) mediated by ABC transporters such as breast cancer resistance protein (BCRP/ABCG2). Here we show that incubation of human breast cancer MDA-MB-231 cells with farnesoid X receptor antagonist guggulsterone (gug) and retinoid X receptor agonist bexarotene (bex) elevated ceramide, a sphingolipid known to induce exosome secretion. The gug+bex combination reduced cellular levels of BCRP to 20% of control cells by inducing its association and secretion with exosomes. Exogenous C6 ceramide also induced secretion of BCRP-associated exosomes, while siRNA-mediated knockdown or GW4869-mediated inhibition of neutral sphingomyelinase 2 (nSMase2), an enzyme generating ceramide, restored cellular BCRP. Immunocytochemistry showed that ceramide elevation and concurrent loss of cellular BCRP was prominent in Aldefluor-labeled breast cancer stem-like cells. These cells no longer excluded the BCRP substrate Hoechst 33342 and showed caspase activation and apoptosis induction. Consistent with reduced BCRP, ABC transporter assays showed that gug+bex increased doxorubicin retention and that the combination of gug+bex with doxorubicin enhanced cell death by more than fivefold. Taken together, our results suggest a novel mechanism by which ceramide induces BCRP secretion and reduces MDR, which may be useful as adjuvant drug treatment for sensitizing breast cancer cells and cancer stem cells to chemotherapy.

AB - Many breast cancer cells acquire multidrug resistance (MDR) mediated by ABC transporters such as breast cancer resistance protein (BCRP/ABCG2). Here we show that incubation of human breast cancer MDA-MB-231 cells with farnesoid X receptor antagonist guggulsterone (gug) and retinoid X receptor agonist bexarotene (bex) elevated ceramide, a sphingolipid known to induce exosome secretion. The gug+bex combination reduced cellular levels of BCRP to 20% of control cells by inducing its association and secretion with exosomes. Exogenous C6 ceramide also induced secretion of BCRP-associated exosomes, while siRNA-mediated knockdown or GW4869-mediated inhibition of neutral sphingomyelinase 2 (nSMase2), an enzyme generating ceramide, restored cellular BCRP. Immunocytochemistry showed that ceramide elevation and concurrent loss of cellular BCRP was prominent in Aldefluor-labeled breast cancer stem-like cells. These cells no longer excluded the BCRP substrate Hoechst 33342 and showed caspase activation and apoptosis induction. Consistent with reduced BCRP, ABC transporter assays showed that gug+bex increased doxorubicin retention and that the combination of gug+bex with doxorubicin enhanced cell death by more than fivefold. Taken together, our results suggest a novel mechanism by which ceramide induces BCRP secretion and reduces MDR, which may be useful as adjuvant drug treatment for sensitizing breast cancer cells and cancer stem cells to chemotherapy.

KW - bile acid

KW - breast cancer resistance protein

KW - cancer stem cells

KW - doxorubicin

KW - exosomes

KW - multidrug resistance

KW - nuclear receptors

KW - sphingolipids

UR - http://www.scopus.com/inward/record.url?scp=84964698520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964698520&partnerID=8YFLogxK

U2 - 10.1002/ijc.29542

DO - 10.1002/ijc.29542

M3 - Article

VL - 137

SP - 1610

EP - 1620

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 7

ER -